Summary & Overview
HCPCS J2212: Methylnaltrexone Injection, 0.1 mg
HCPCS Level II code J2212 denotes an injection of methylnaltrexone, 0.1 mg. This drug-specific billing code is used to report discrete dosing units of methylnaltrexone administered via injection, typically in outpatient infusion suites or physician offices. Methylnaltrexone is employed in the management of opioid-induced constipation and related indications, making accurate coding important for clinical documentation, medication inventory, and payer reimbursement processes nationwide.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context and service setting, plus benchmark and policy-relevant content where available. The publication outlines typical billing practices associated with drug-unit reporting, summarizes payer coverage considerations, and highlights areas where billing clarity affects claims processing and utilization tracking. Where input data is not available, the report notes that specific items are unavailable rather than inferring details.
This summary is written for a national audience and emphasizes the administrative and clinical significance of accurate reporting for HCPCS Level II code J2212 in ambulatory medication administration settings.
Billing Code Overview
HCPCS Level II code J2212 represents an injection of methylnaltrexone, 0.1 mg. The service is a medication administration involving a specific dosage unit of methylnaltrexone provided as an injectable formulation. The typical site of service for this code is outpatient infusion/clinic or physician office administration, including settings where parenteral medications are administered to ambulatory patients.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving treatment for opioid-induced constipation (OIC) who has an inadequate response to conventional laxative therapy. The patient presents to an outpatient infusion clinic, oncology clinic, or ambulatory procedure area for parenteral administration of a targeted peripherally acting mu-opioid receptor antagonist. The treating clinician (often a gastroenterologist, palliative medicine specialist, pain medicine physician, or oncology clinician) reviews medication history and confirms ongoing opioid therapy, documents failed trials of oral laxatives, obtains informed consent, and verifies weight and dosing. A licensed nurse prepares and administers the subcutaneous injection of J2212 (methylnaltrexone 0.1 mg per unit) and monitors the patient for immediate adverse effects and bowel response for a short observation period before discharge. Billing is submitted for the drug itself using J2212, with appropriate administration and facility codes submitted separately as applicable to the site of service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of the vial is discarded and documentation supports billing only for administered dose |